Mesoblast (MESO) Short-Term Debt repayments (2020 - 2022)
Mesoblast recorded quarterly Short-Term Debt repayments of -$429000.0 in Q2 2022, up 62.53% quarter-over-quarter from -$1.1 million in Q1 2022, and up 48.38% year-over-year from -$289131.4 in Q2 2021.
Mesoblast's Short-Term Debt repayments history runs 3 years deep, the most recent figure standing at -$429000.0 for Q2 2022.
- In Q2 2022, Short-Term Debt repayments rose 48.38% year-over-year to -$429000.0; the TTM figure through Jun 2022 stood at -$2.8 million (up 4.88% YoY), while the FY2022 annual figure was -$2.8 million, up 4.88% from the prior year.
- Short-Term Debt repayments came in at -$429000.0 for Q2 2022 at Mesoblast, up from -$1.1 million in the prior quarter.
- In the past five years, Short-Term Debt repayments ranged from a high of -$429000.0 in Q2 2022 to a low of -$1.1 million in Q1 2022.
- A 3-year average of -$714875.0 and a median of -$690500.0 in 2020 frame the typical range for Short-Term Debt repayments.
- On a YoY basis, Short-Term Debt repayments climbed as much as 48.38% in 2022 and fell as far as 84.68% in 2022.
- Mesoblast's Short-Term Debt repayments stood at -$785000.0 in 2020, then surged by 32.74% to -$528000.0 in 2021, then advanced by 18.75% to -$429000.0 in 2022.
- According to Business Quant data, Short-Term Debt repayments over the past three periods registered -$429000.0, -$1.1 million, and -$528000.0 for Q2 2022, Q1 2022, and Q4 2021 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 102,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Mesoblast | 23.40 Bn | 23.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -429,000.00 |
| Jun 30, 2022 | -429,000.00 |
| Mar 31, 2022 | -1.15 Mn |
| Mar 31, 2022 | -1.15 Mn |
| Dec 31, 2021 | -528,000.00 |
| Dec 31, 2021 | -528,000.00 |
| Sep 30, 2021 | -686,000.00 |
| Sep 30, 2021 | -686,000.00 |
| Jun 30, 2021 | -831,000.00 |
| Jun 30, 2021 | -831,000.00 |
| Mar 31, 2021 | -620,000.00 |
| Mar 31, 2021 | -620,000.00 |
| Dec 31, 2020 | -785,000.00 |
| Dec 31, 2020 | -785,000.00 |
| Sep 30, 2020 | -695,000.00 |
| Sep 30, 2020 | -695,000.00 |